Amgen and Daiichi Sankyo Co., entered a collaboration and license agreement for the development and commercialization of denosumab in Japan. Denosumab is a fully human monoclonal antibody that targets RANK Ligand (an essential mediator of cells that break down bone) and is being investigated in a broad range of bone loss conditions including osteoporosis and bone metastases. Daiichi Sankyo will have exclusive rights to develop and commercialize denosumab in Japan in post-menopausal osteopor...